San Francisco, CA (UroToday.com) — The American Urological Association (AUA) announced amendments to its clinical guideline on Renal Masses and Localized Renal Cancer, originally published in 2013 and was updated in 2017, based on an additional literature search conducted through October 2020.
Clinical trials have shown an overall survival (OS) benefit associated with first-line immunotherapy (IT) and combination targeted therapy (TT) and IT regimens compared with TT among patients with metastatic clear cell renal cell carcinoma (RCC).
Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomarkers is still an unmet clinical need.
Renal function is frequently impaired in the patients with upper tract urothelial carcinoma. We aimed to evaluate the impact of renal function and its change after surgery on survival rates in patients with upper tract urothelial carcinoma after nephroureterectomy.
Checkpoint inhibitors and currently approved cellular products for metastatic castration-resistant prostate cancer have not resulted in revolutionary changes in outcomes compared to other solid tumors.
PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted.
To assess the relationship between the volume of the index lesion (IL) measured at mpMRI (MRIvol) and at radical prostatectomy (RPvol), stratifying it according to PI-RADS score. We identified 332 men with a positive mpMRI (single lesion with PI-RADS≥3) who underwent systematic plus targeted biopsy and subsequent RP at two tertiary referral centres between 2013 […]
Exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving apalutamide (240 mg/day) or placebo, with continuous androgen-deprivation therapy (ADT), in the phase 3, randomized, double-blind placebo-controlled TITAN trial (NCT02489318).
The objectives of this exploratory study were to investigate the feasibility of multidimensional diffusion magnetic resonance imaging (MddMRI) in assessing diffusion heterogeneity at both a macroscopic and microscopic level in prostate cancer (PCa).
For >50 years the tumor, node, metastasis (TNM) classification model of malignant tumors has been the main resource for clinicians, pathologists, radiologists and public health professionals ensuring a homogeneous classification and patients’ management based on common staging and prognosis factors.
